Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 639


Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.

Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, Kufe D.

Oncogene. 2019 Oct 1. doi: 10.1038/s41388-019-1038-5. [Epub ahead of print]


MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C, Long MD, Hu Q, Liu S, Fushimi A, Yamashita N, Kui L, Hong D, Yamamoto M, Miyo M, Hiraki M, Maeda T, Suzuki Y, Samur MK, Kufe D.

Cancer Res. 2019 Sep 13. pii: canres.1034.2019. doi: 10.1158/0008-5472.CAN-19-1034. [Epub ahead of print]


MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.

Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yasumizu Y, Hong D, Samur M, Kufe D.

Oncogene. 2019 Aug 21. doi: 10.1038/s41388-019-0940-1. [Epub ahead of print] Erratum in: Oncogene. 2019 Oct 1;:.


Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Hata T, Rajabi H, Yamamoto M, Jin C, Ahmad R, Zhang Y, Kui L, Li W, Yasumizu Y, Hong D, Miyo M, Hiraki M, Maeda T, Suzuki Y, Takahashi H, Samur M, Kufe D.

Mol Cancer Ther. 2019 Oct;18(10):1744-1754. doi: 10.1158/1535-7163.MCT-19-0156. Epub 2019 Jul 15.


Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.

Nahas MR, Stroopinsky D, Rosenblatt J, Cole L, Pyzer AR, Anastasiadou E, Sergeeva A, Ephraim A, Washington A, Orr S, McMasters M, Weinstock M, Jain S, Leaf RK, Ghiasuddin H, Rahimian M, Liegel J, Molldrem JJ, Slack F, Kufe D, Avigan D.

Br J Haematol. 2019 May;185(4):679-690. doi: 10.1111/bjh.15818. Epub 2019 Mar 3.


MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, Maeda T, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.

Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259. Epub 2019 Mar 1.


Corrigendum to 'Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy' NANO 14 (2018) 1301-1313.

Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK, Kharbanda S, Kufe D, Singh H.

Nanomedicine. 2018 Oct;14(7):2129. doi: 10.1016/j.nano.2018.07.001. Epub 2018 Jul 24. No abstract available.


Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

Panchamoorthy G, Jin C, Raina D, Bharti A, Yamamoto M, Adeebge D, Zhao Q, Bronson R, Jiang S, Li L, Suzuki Y, Tagde A, Ghoroghchian PP, Wong KK, Kharbanda S, Kufe D.

JCI Insight. 2018 Jun 21;3(12). pii: 99880. doi: 10.1172/jci.insight.99880. eCollection 2018 Jun 21.


MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.

Stroopinsky D, Rajabi H, Nahas M, Rosenblatt J, Rahimian M, Pyzer A, Tagde A, Kharbanda A, Jain S, Kufe T, Leaf RK, Anastasiadou E, Bar-Natan M, Orr S, Coll MD, Palmer K, Ephraim A, Cole L, Washington A, Kufe D, Avigan D.

J Cell Mol Med. 2018 May 15. doi: 10.1111/jcmm.13662. [Epub ahead of print]


Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer.

Hiraki M, Maeda T, Mehrotra N, Jin C, Alam M, Bouillez A, Hata T, Tagde A, Keating A, Kharbanda S, Singh H, Kufe D.

Signal Transduct Target Ther. 2018 May 12;3:13. doi: 10.1038/s41392-018-0013-x. eCollection 2018.


Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy.

Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK, Kharbanda S, Kufe D, Singh H.

Nanomedicine. 2018 Jun;14(4):1301-1313. doi: 10.1016/j.nano.2018.03.010. Epub 2018 Apr 8. Erratum in: Nanomedicine. 2018 Oct;14(7):2129.


MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.

Rajabi H, Hiraki M, Kufe D.

Oncogene. 2018 Apr;37(16):2079-2088. doi: 10.1038/s41388-017-0096-9. Epub 2018 Jan 30. Review.


MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D.

Cancer Res. 2018 Jan 1;78(1):205-215. doi: 10.1158/0008-5472.CAN-17-1636. Epub 2017 Dec 20.


CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.

Sakakibara K, Sato T, Kufe DW, VonHoff DD, Kawabe T.

Oncotarget. 2017 Sep 16;8(45):78277-78288. doi: 10.18632/oncotarget.20968. eCollection 2017 Oct 3.


CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding.

Saito N, Mine N, Kufe DW, Von Hoff DD, Kawabe T.

Oncotarget. 2017 Jun 22;8(43):74006-74018. doi: 10.18632/oncotarget.18598. eCollection 2017 Sep 26.


Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.

Tagde A, Markert T, Rajabi H, Hiraki M, Alam M, Bouillez A, Avigan D, Anderson K, Kufe D.

Oncotarget. 2017 Aug 10;8(41):69237-69249. doi: 10.18632/oncotarget.20144. eCollection 2017 Sep 19.


CBP501 suppresses macrophage induced cancer stem cell like features and metastases.

Mine N, Yamamoto S, Saito N, Sato T, Sakakibara K, Kufe DW, VonHoff DD, Kawabe T.

Oncotarget. 2017 Jul 17;8(38):64015-64031. doi: 10.18632/oncotarget.19292. eCollection 2017 Sep 8.


MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.

Bouillez A, Adeegbe D, Jin C, Hu X, Tagde A, Alam M, Rajabi H, Wong KK, Kufe D.

Oncoimmunology. 2017 Jul 5;6(9):e1338998. doi: 10.1080/2162402X.2017.1338998. eCollection 2017.


MUC1-C activates EZH2 expression and function in human cancer cells.

Rajabi H, Hiraki M, Tagde A, Alam M, Bouillez A, Christensen CL, Samur M, Wong KK, Kufe D.

Sci Rep. 2017 Aug 7;7(1):7481. doi: 10.1038/s41598-017-07850-0.


Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Jain S, Washington A, Leaf RK, Bhargava P, Clark RA, Kupper TS, Stroopinsky D, Pyzer A, Cole L, Nahas M, Apel A, Rosenblatt J, Arnason J, Kufe D, Avigan D.

Mol Cancer Ther. 2017 Oct;16(10):2304-2314. doi: 10.1158/1535-7163.MCT-17-0060. Epub 2017 Jul 20.


MUC1-C is a target in lenalidomide resistant multiple myeloma.

Yin L, Tagde A, Gali R, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Br J Haematol. 2017 Sep;178(6):914-926. doi: 10.1111/bjh.14801. Epub 2017 Jun 23.


MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D.

Leukemia. 2017 Dec;31(12):2780-2790. doi: 10.1038/leu.2017.163. Epub 2017 May 30.


Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system.

Shukla V, Dalela M, Vij M, Weichselbaum R, Kharbanda S, Ganguli M, Kufe D, Singh H.

Nanomedicine. 2017 Jul;13(5):1833-1839. doi: 10.1016/j.nano.2017.03.004. Epub 2017 Mar 23.


MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.

Rajabi H, Kufe D.

Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122. doi: 10.1016/j.bbcan.2017.03.003. Epub 2017 Mar 14. Review.


MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.

Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D.

Oncogene. 2017 Jul 13;36(28):4037-4046. doi: 10.1038/onc.2017.47. Epub 2017 Mar 13.


Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.

Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D.

Mol Cancer. 2017 Feb 2;16(1):33. doi: 10.1186/s12943-017-0608-9.


MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.

Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D.

Blood. 2017 Mar 30;129(13):1791-1801. doi: 10.1182/blood-2016-07-730614. Epub 2017 Jan 26.


Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.


MUC1-C drives DNA methylation in cancer.

Rajabi H, Tagde A, Kufe D.

Aging (Albany NY). 2016 Dec 28;8(12):3155-3156. doi: 10.18632/aging.101153. No abstract available.


Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.


MUC1-C activates BMI1 in human cancer cells.

Hiraki M, Maeda T, Bouillez A, Alam M, Tagde A, Hinohara K, Suzuki Y, Markert T, Miyo M, Komura K, Ahmad R, Rajabi H, Kufe D.

Oncogene. 2017 May 18;36(20):2791-2801. doi: 10.1038/onc.2016.439. Epub 2016 Nov 28.


MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.

Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D.

Oncotarget. 2016 Jun 28;7(26):38974-38987. doi: 10.18632/oncotarget.9777.


Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK.

JCI Insight. 2016 Sep 8;1(14):e89014. doi: 10.1172/jci.insight.89014.


MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.

Alam M, Bouillez A, Tagde A, Ahmad R, Rajabi H, Maeda T, Hiraki M, Suzuki Y, Kufe D.

Mol Cancer Res. 2016 Dec;14(12):1266-1276. Epub 2016 Sep 22.


MUC1 in hematological malignancies.

Stroopinsky D, Kufe D, Avigan D.

Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27. Review.


MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.

Hiraki M, Suzuki Y, Alam M, Hinohara K, Hasegawa M, Jin C, Kharbanda S, Kufe D.

Sci Rep. 2016 May 24;6:26643. doi: 10.1038/srep26643.


DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells.

Rajabi H, Tagde A, Alam M, Bouillez A, Pitroda S, Suzuki Y, Kufe D.

Oncogene. 2016 Dec 15;35(50):6439-6445. doi: 10.1038/onc.2016.180. Epub 2016 May 23.


Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.

Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP, Kufe D.

Oncotarget. 2016 Mar 15;7(11):11756-69. doi: 10.18632/oncotarget.7598.


MUC1-C drives MYC in multiple myeloma.

Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Blood. 2016 May 26;127(21):2587-97. doi: 10.1182/blood-2015-07-659151. Epub 2016 Feb 23.


Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.

Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D.

Cancer Res. 2016 Mar 15;76(6):1538-48. doi: 10.1158/0008-5472.CAN-15-1804. Epub 2016 Feb 1.


Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.

Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, Kufe D.

PLoS One. 2015 Aug 12;10(8):e0135156. doi: 10.1371/journal.pone.0135156. eCollection 2015.


Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D.

Blood. 2015 Jul 16;126(3):354-62. doi: 10.1182/blood-2015-02-628149. Epub 2015 Jun 5.


Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

Hasegawa M, Sinha RK, Kumar M, Alam M, Yin L, Raina D, Kharbanda A, Panchamoorthy G, Gupta D, Singh H, Kharbanda S, Kufe D.

Clin Cancer Res. 2015 May 15;21(10):2338-47. doi: 10.1158/1078-0432.CCR-14-3000. Epub 2015 Feb 23.


MUC1-C activates the TAK1 inflammatory pathway in colon cancer.

Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT, Weichselbaum R, Kufe D.

Oncogene. 2015 Oct 1;34(40):5187-97. doi: 10.1038/onc.2014.442. Epub 2015 Feb 9.


MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.

Alam M, Ahmad R, Rajabi H, Kufe D.

Mol Cancer Res. 2015 Mar;13(3):449-60. doi: 10.1158/1541-7786.MCR-14-0363. Epub 2014 Nov 3.


CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.

Saito N, Sakakibara K, Sato T, Friedman JM, Kufe DW, VonHoff DD, Kawabe T.

Mol Cancer Ther. 2014 Dec;13(12):3013-23. doi: 10.1158/1535-7163.MCT-14-0064. Epub 2014 Sep 24.


MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.

Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D.

Oncotarget. 2014 Oct 15;5(19):8893-905.


Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.

Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK, Kufe D.

Clin Cancer Res. 2014 Nov 1;20(21):5423-34. doi: 10.1158/1078-0432.CCR-13-3168. Epub 2014 Sep 4.


Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.

Mine N, Yamamoto S, Kufe DW, Von Hoff DD, Kawabe T.

Mol Cancer Ther. 2014 Sep;13(9):2215-25. doi: 10.1158/1535-7163.MCT-13-0808. Epub 2014 Jul 22.


Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.

Alam M, Rajabi H, Ahmad R, Jin C, Kufe D.

Oncotarget. 2014 May 15;5(9):2622-34.

Supplemental Content

Support Center